Pfost Dale R Form 3 April 02, 2007

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

EXEGENICS INC., Â 4400

Person *

Pfost Dale R

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

03/29/2007

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

eXegenics Inc [EXEG]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

BISCAYNE BOULEVARD,

SUITE 900

(Street)

Director _X__ Officer

10% Owner Other

6. Individual or Joint/Group (give title below) (specify below) Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

MIAMI, FLÂ 33137

(City) (State) (Zip)

(Instr. 4)

1. Title of Security

Beneficially Owned

2. Amount of Securities

(Instr. 4)

3.

President

Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership Form: (Instr. 5)

Direct (D) or Indirect (I)

(Instr. 5)

Â Common Stock, \$.01 par value 1,687,261 $\mathbf{D}^{(1)}$

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security 2. Date Exercisable and (Instr. 4)

Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise

6. Nature of Indirect 5. Ownership Beneficial

Ownership

(Instr. 5)

Price of Derivative Derivative Security:

Form of

Edgar Filing: Pfost Dale R - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series C Convertible Preferred Stock	(2)	(2)	Common Stock	518,900	\$ 0	D	Â
Warrant (Right to Buy)	(3)	03/27/2017	Common Stock	64,868	\$ 0.002	D	Â
Warrant (Right to Buy)	(3)	03/27/2017	Common Stock	68,852	\$ 0.6728	D	Â
Warrant (Right to Buy)	(3)	03/27/2017	Common Stock	68,852	\$ 0.8473	D	Â
Warrant (Right to Buy)	(3)	03/27/2017	Common Stock	68,852	\$ 1.0466	D	Â
Stock Option (Right to Buy)	(4)	09/24/2014	Series C Convertible Preferred Stock	7,317	\$ 31.8	D	Â
Stock Option (Right to Buy)	(5)	12/11/2013	Common Stock	430,722	\$ 0.04	D	Â
Stock Option (Right to Buy)	(4)	09/24/2014	Common Stock	225,740	\$ 0.04	D	Â
Stock Option (Right to Buy)	(6)	02/15/2015	Common Stock	1,297,357	\$ 0.04	D	Â
Stock Option (Right to Buy)	(7)	11/01/2015	Common Stock	311,365	\$ 0.05	D	Â
Stock Option (Right to Buy)	(8)	01/01/2016	Common Stock	311,365	\$ 0.05	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships				
F 9	Director	10% Owner	Officer	Other		
Pfost Dale R						
EXEGENICS INC.	Â	Â	President	Â		
4400 BISCAYNE BOULEVARD, SUITE 900	Λ	А	A Tresident	Λ		
MIAMI, FL 33137						

Signatures

/s/ Dale R. Pfost	03/30/2007		
**Signature of Reporting Person	Date		

Reporting Owners 2

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1,081,116 of these shares are owned jointly by Mr. Pfost and his wife.
- (2) These shares are currently exercisable and do not expire.
- (3) These warrants are currently exercisable.
- (4) These options are fully vesed.
- (5) 349,657 of these options are presently fully vested. The balance will vest monthly until fully vested in December 2007.
- (6) 675,705 of these options are presently fully vested. The balance will vest monthly until fully vested in February 2009..
- (7) 103,785 of these options are presently fully vested. The balance will vest monthly until fully vested in November 2009.
- (8) 90,814 of these options are presently fully vested. The balance will vest monthly until fully vested in January 2010.

Â

Remarks:

All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. an Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.